Volition RX
Volition's goal is to make its non-invasive cancer blood tests as common and simple to use as existing diabetic and cholesterol tests on similar formats.
Home
About Us
About Volition
Management Team
Board of Directors
Scientific Advisory Board
Social Responsibility
Cancer
Products
Nucleosomics
Hypergenomics
Endometriosis
Media
Newsroom
Volition In The News
Events
Downloads
Investors
Share Information
Investor Events
Investor FAQs
Investor Reports
Investor Downloads
Safe Harbor Statement
Careers
Contact
Revolutionizing Cancer Diagnosis
Sitemap
Home
About Us
Volition
Management Team
Board of Directors
Scientific Advisory Board
Social Responsibility
Cancer
Products
Nucleosomics
Hypergenomics
Endometriosis
Media
Newsroom
Events
Downloads
Sitemap-Newsroom
Racepoint Group Appointed by VolitionRx to Raise Awareness of its new Early-Stage Cancer Diagnostic
VolitionRx Files Two Patent Applications
New Hire Head of US Operations
New Collaboration with Wales Cancer Bank
Volition Launches NuQ® Epigenetic Immunoassays for Research Use
VolitionRx’s Preliminary Diagnostic Clinical Trial Results Show High Sensitivity and Specificity for Colon, Breast and Lung Cancers
VolitionRX débute un Essai Clinique sur le cancer du colon
VolitionRX to Begin Prospective Clinical Trial in Colon Cancer
VolitionRX CEO Issues Letter to Shareholders
Collaboration agreement signed with Dr Stefan Holdenrieder of University Hospital Bonn
Sitemap-Events
Careers
Contact
Sitemap
Dictionary
NUCLEOSOMICS.COM
Copyright © 2011 VolitionRX. All Rights Reserved
VolitionRx - Singapore - 1 Scotts Road - #24-05 Shaw Centre - Singapore 228208
VolitionRx - Belgium (Centre Technologique) - Rue du Séminaire, 20A - B-5000 Namur - Belgium